Literature DB >> 21854751

Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain.

Katherine J Kopeikina1, George A Carlson, Rose Pitstick, Adam E Ludvigson, Alan Peters, Jennifer I Luebke, Robert M Koffie, Matthew P Frosch, Bradley T Hyman, Tara L Spires-Jones.   

Abstract

Neurofibrillary tangles (NFT), intracellular inclusions of abnormal fibrillar forms of microtubule associated protein tau, accumulate in Alzheimer's disease (AD) and other tauopathies and are believed to cause neuronal dysfunction, but the mechanism of tau-mediated toxicity are uncertain. Tau overexpression in cell culture impairs localization and trafficking of organelles. Here we tested the hypothesis that, in the intact brain, changes in mitochondrial distribution occur secondary to pathological changes in tau. Array tomography, a high-resolution imaging technique, was used to examine mitochondria in the reversible transgenic (rTg)4510, a regulatable transgenic, mouse model and AD brain tissue. Mitochondrial distribution is progressively disrupted with age in rTg4510 brain, particularly in somata and neurites containing Alz50-positive tau aggregates. Suppression of soluble tau expression with doxycycline resulted in complete recovery of mitochondrial distribution, despite the continued presence of aggregated tau. The effect on mitochondrial distribution occurs without concomitant alterations in neuropil mitochondrial size, as assessed by both array tomography and electron microscopy. Similar mitochondrial localization alterations were also observed in human AD tissue in Alz50+ neurons, confirming the relevance of tau to mitochondrial trafficking observed in this animal model. Because abnormalities reverted to normal if soluble tau was suppressed in rTg4510 mice, even in the continued presence of fibrillar tau inclusions, we suggest that soluble tau plays an important role in mitochondrial abnormalities, which likely contribute to neuronal dysfunction in AD.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21854751      PMCID: PMC3181340          DOI: 10.1016/j.ajpath.2011.07.004

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

1.  A pyramid approach to subpixel registration based on intensity.

Authors:  P Thévenaz; U E Ruttimann; M Unser
Journal:  IEEE Trans Image Process       Date:  1998       Impact factor: 10.856

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

Review 3.  Neuronal microtubules: when the MAP is the roadblock.

Authors:  Peter W Baas; Liang Qiang
Journal:  Trends Cell Biol       Date:  2005-04       Impact factor: 20.808

Review 4.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

5.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

6.  A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.

Authors:  Giuseppina Amadoro; Veronica Corsetti; Annarita Stringaro; Marisa Colone; Simona D'Aguanno; Giovanni Meli; Mariateresa Ciotti; Giuseppe Sancesario; Antonino Cattaneo; Rossana Bussani; Delio Mercanti; Pietro Calissano
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 7.  Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases.

Authors:  P Hemachandra Reddy; Tejaswini P Reddy; Maria Manczak; Marcus J Calkins; Ulziibat Shirendeb; Peizhong Mao
Journal:  Brain Res Rev       Date:  2010-12-08

8.  Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model.

Authors:  Heng Du; Lan Guo; Shiqiang Yan; Alexander A Sosunov; Guy M McKhann; Shirley ShiDu Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

9.  Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease.

Authors:  Rodrigo A Quintanilla; Tori A Matthews-Roberson; Philip J Dolan; Gail V W Johnson
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

10.  Characterization of genetically targeted neuron types in the zebrafish optic tectum.

Authors:  Estuardo Robles; Stephen J Smith; Herwig Baier
Journal:  Front Neural Circuits       Date:  2011-02-22       Impact factor: 3.492

View more
  120 in total

1.  PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease.

Authors:  Patricia Martín-Maestro; Ricardo Gargini; George Perry; Jesús Avila; Vega García-Escudero
Journal:  Hum Mol Genet       Date:  2015-12-31       Impact factor: 6.150

Review 2.  Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress.

Authors:  Mohammed Akbar; Musthafa Mohamed Essa; Ghazi Daradkeh; Mohamed A Abdelmegeed; Youngshim Choi; Lubna Mahmood; Byoung-Joon Song
Journal:  Brain Res       Date:  2016-02-13       Impact factor: 3.252

Review 3.  Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology.

Authors:  Bradley T Hyman; Junying Yuan
Journal:  Nat Rev Neurosci       Date:  2012-05-18       Impact factor: 34.870

Review 4.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

Review 5.  Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.

Authors:  Judit M Perez Ortiz; Russell H Swerdlow
Journal:  Br J Pharmacol       Date:  2019-03-06       Impact factor: 8.739

6.  Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage.

Authors:  Maria Manczak; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2012-02-24       Impact factor: 6.150

7.  Tau promotes neurodegeneration via DRP1 mislocalization in vivo.

Authors:  Brian DuBoff; Jürgen Götz; Mel B Feany
Journal:  Neuron       Date:  2012-08-23       Impact factor: 17.173

8.  Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy.

Authors:  Johanna L Crimins; Anne B Rocher; Jennifer I Luebke
Journal:  Acta Neuropathol       Date:  2012-09-14       Impact factor: 17.088

Review 9.  The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.

Authors:  Johanna L Crimins; Amy Pooler; Manuela Polydoro; Jennifer I Luebke; Tara L Spires-Jones
Journal:  Ageing Res Rev       Date:  2013-03-22       Impact factor: 10.895

10.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.